Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Study Overview

• Status: Completed
• Conditions: Major Depressive Disorder
• Intervention / Treatment: Drug: Lumateperone; Drug: Placebo

Detailed Description

The study will be conducted in three periods:

• Screening Period (up to 2 weeks) during which patient eligibility will be assessed;
• Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
• Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.

• Study Type: Interventional
• Enrollment (Actual): 480
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Ciudad Autonoma de Buenos Aires, Argentina, C10154ABQ
    • Clinical Site
  • Ciudad Autonoma Buenos Aires
    • Ciudad Autonoma de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina, 1058 AAJ
      • Clinical Site
  • Cordoba
    • Córdoba, Cordoba, Argentina, 5000FJF
      • Clinical Site
    • Córdoba, Cordoba, Argentina, 5000
      • Clinical Site
    • Córdoba, Cordoba, Argentina, 5009
      • Clinical Site
    • Córdoba, Cordoba, Argentina, X5003DCE
      • Clinical Site
  • Mendoza
    • Ciudad de Mendoza, Mendoza, Argentina, M5502AHV
      • Clinical Site
  • Santa Fe
    • Rosario, Santa Fe, Argentina, S2000QJI
      • Clinical Site
• Bulgaria
  • Plovdiv, Bulgaria, 4004
    • Clinical Site
  • Sofia, Bulgaria, 1408
    • Clinical Site
  • Sofia, Bulgaria, 1680
    • Clinical Site
  • Targovishte, Bulgaria, 7700
    • Clinical Site
• Finland
  • Helsinki, Finland, 00100
    • Clinical Site
  • Oulu, Finland, 90100
    • Clinical Site
• Germany
  • Bad Homburg, Germany, 61348
    • Clinical Site
  • Freiburg im Breisgau, Germany, 79104
    • Clinical Site
  • Hamburg, Germany, 20253
    • Clinical Site
  • Mittweida, Germany, 09648
    • Clinical Site
  • Schwerin, Germany, 19053
    • Clinical Site
  • Westerstede, Germany, 26655
    • Clinical Site
• Poland
  • Bełchatów, Poland, 97-400
    • Clinical Site
  • Białystok, Poland, 15-404
    • Clinical Site
  • Białystok, Poland, 15-464
    • Clinical Site
  • Białystok, Poland, 15-879
    • Clinical Site
  • Bydgoszcz, Poland, 85-080
    • Clinical Site
  • Gdańsk, Poland, 80-546
    • Clinical Site
  • Gorlice, Poland, 38-300
    • Clinical Site
  • Leszno, Poland, 64-100
    • Clinical Site
  • Pruszcz Gdański, Poland, 83-000
    • Clinical Site
  • Toruń, Poland, 87-100
    • Clinical Site
  • Wrocław, Poland, 50-414
    • Clinical Site
• Sweden
  • Lund, Sweden, 22222
    • Clinical Site
  • Stockholm, Sweden, 11329
    • Clinical Site
• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72211
      • Clinical Site
    • Rogers, Arkansas, United States, 72758
      • Clinical Site
  • California
    • Newport Beach, California, United States, 92660
      • Clinical Site
    • Riverside, California, United States, 92506
      • Clinical Site
    • San Diego, California, United States, 92103
      • Clinical Site
  • Florida
    • Palm Bay, Florida, United States, 32905
      • Clinical Site
    • West Palm Beach, Florida, United States, 33407
      • Clinical Site
  • Georgia
    • Atlanta, Georgia, United States, 30329
      • Clinical Site
  • Kansas
    • Overland Park, Kansas, United States, 66211
      • Clinical Site
  • Maryland
    • Gaithersburg, Maryland, United States, 20877
      • Clinical Site
  • Mississippi
    • Flowood, Mississippi, United States, 39232
      • Clinical Site
  • New York
    • Brooklyn, New York, United States, 11235
      • Clinical Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28211
      • Clinical Site
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18104
      • Clinical Site
    • Media, Pennsylvania, United States, 19063
      • Clinical Site
    • Plymouth Meeting, Pennsylvania, United States, 19462
      • Clinical Site
  • Washington
    • Bellevue, Washington, United States, 98007
      • Clinical Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female patients between the ages of 18 and 65 years, inclusive;

2. Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the MINI and meets all of the following criteria:

   1. The start of the current major depressive episode (MDE) is at least 8 weeks but not more than 18 months prior to Screening;
   2. Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
   3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening (Visit 1) and at Baseline;
   4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
   5. Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.

3. Currently having an inadequate response to ADT (less than 50% improvement) as confirmed by the Investigator and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:

   1. citalopram/escitalopram
   2. fluoxetine
   3. paroxetine
   4. sertraline
   5. duloxetine
   6. levomilnacipran/milnacipran (if locally approved for MDD)
   7. venlafaxine/desvenlafaxine
   8. bupropion
   9. vilazodone
   10. vortioxetine

Exclusion Criteria:

1. Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:

   1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
   2. Bipolar Disorder;

2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:

   1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses.
   2. Eating disorder;
   3. Substance use disorders (excluding nicotine);
   4. Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
   5. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;

5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:

   1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
   2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
   3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
   4. The patient is considered to be in imminent danger to him/herself or others.
6. The patient has a first MDE at age 60 years or older.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Matching capsules administered orally, once daily.
Experimental: Lumateperone 42 mg	Drug: Lumateperone; Lumateperone 42 mg capsules administered orally, once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Montgomery-Asberg Depression Rating Scale	Change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.	Day 43

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Global Impression Scale-Severity	Change from baseline to Day 43 in the Clinical Global Impression Scale-Severity (CGI-S). The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).	Day 43

Collaborators and Investigators

• Sponsor: Intra-Cellular Therapies, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2021
• Primary Completion (Actual): April 12, 2024
• Study Completion (Actual): April 12, 2024

Study Registration Dates

• First Submitted: September 20, 2021
• First Submitted That Met QC Criteria: September 20, 2021
• First Posted (Actual): September 29, 2021

Study Record Updates

• Last Update Posted (Actual): May 9, 2025
• Last Update Submitted That Met QC Criteria: May 1, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: Adjunctive MDD Therapy
• Additional Relevant MeSH Terms: Mental Disorders; Behavioral Symptoms; Mood Disorders; Depression; Depressive Disorder; Depressive Disorder, Major
• Other Study ID Numbers: ITI-007-502

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No